The global Glycogen Storage Disease Market is projected to experience a steady growth in revenue over the forecast period. This growth is primarily driven by factors such as the continuous use of long-term treatments, the introduction of new medications, and the high cost of treatment.

Glycogen storage disease (GSD) is an inherited disorder that affects the body's ability to store or break down the complex sugar glycogen due to an enzyme deficiency. It can have various types and impacts different parts of the body, including the muscles and liver. GSD results in the inability to convert stored glycogen into glucose for energy, leading to unstable blood glucose levels. Type I GSD, which is inherited in an autosomal recessive manner, is characterized by excessive glycogen and fat buildup in the liver and kidneys, causing enlargement and growth impairment. Mutations in the G6PC gene or SLC37A4 gene are associated with GSDI, preventing the breakdown of glycogen and resulting in the accumulation of glycogen and fat in tissues, as well as low blood glucose levels. Additionally, enzyme deficiency leads to an imbalance or excessive buildup of other metabolites such as lactates, uric acid, lipids, and triglycerides.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5508

There are various types of glycogen storage diseases, including Lewis' disease (Type 0), von Gierke's disease (Type I), Pompe's disease (Type II), Forbes-Cori disease (Type III), Andersen's disease (Type IV), McArdle's disease (Type V), Hers' disease (Type VI), Tarui's disease (Type VII), and Fanconi-Bickel syndrome (Type XI), among others.

Several factors contribute to the growth of the global glycogen storage disease market. The National Library of Medicine reports a prevalence rate of 1 in 20,000 to 1 in 40,000 people in Europe, Canada, and the U.S. with glycogen storage disease. However, this incidence may be underestimated due to undiagnosed mild variants and untreated cases that can result in fetal or neonatal death. The frequency of glycogen storage disease also varies based on ethnicity, with individuals of North African Jewish heritage having a higher likelihood of having type 3 GSD. The old order Mennonite population also exhibits a higher prevalence of type 6 GSD compared to the general population.

On the other hand, the global market for therapies targeting glycogen storage diseases faces some constraints to revenue growth. These include the lack of treatment alternatives, high treatment costs, and the heterogeneity of the condition.

Nevertheless, there are opportunities in the global glycogen storage disease market. Factors such as the need to improve healthcare quality, the rise in viral infections and immune disorders, and the development of novel diagnostic technologies present potential prospects for market participants. The demand for novel drug development to treat glycogen storage diseases, along with the presence of potential candidates, can create lucrative opportunities for players in the market.

To know more about the latest insights of the report, visit @ https://www.reportsanddata.com/request-latest-insight/5508

In terms of geographical market scenario, North America is expected to hold the largest market share due to increased patient awareness of rare disorders and a well-developed healthcare infrastructure. The Asia Pacific region, on the other hand, is anticipated to experience significant revenue growth due to the rising incidence of glycogen storage disorders and the costs associated with developing healthcare infrastructure.

Key market trends and innovations include the FDA update on the FORTIS clinical trial of AT845 for adults with late-onset Pompe disease, the dosing of the first patient with UX053 (an mRNA therapy for glycogen storage disease type III), and the regulatory approval for the Phase 2 study of ARCT-810 mRNA (for the deficiency of Ornithine Transcarbamylase). These developments indicate ongoing advancements in treatment options for glycogen storage diseases.

The competitive landscape of the market involves the adoption of organic and inorganic strategies. For example, the U.S. Food and Drug Administration approved Nexviazyme for intravenous infusion to treat patients with late-onset Pompe disease. Additionally, Soleno Therapeutics announced FDA designation of Diazoxide Choline as an orphan drug for the treatment of glycogen storage disease type 1a. Major companies in the market include Shire PLC, Pfizer, Inc., Sanofi S.A., BioMarin Pharmaceutical Inc., Actelion Ltd, Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Amicus Therapeutics, Inc., Merck & Co., Inc., Takeda Pharmaceutical, AstraZeneca plc, and Boehringer Ingelheim.

The market is segmented based on disease type (including Gaucher's disease, Fabry disease, Pompe syndrome, mucopolysaccharidosis, and others), treatment type (enzye replacement therapy), route of administration (oral, parenteral, and others), distribution channel (online and offline), end user (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa).

Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5508

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs